Program
elamipretide
Also written as “MTP-131”, “Elamipretide” and “Bendavia”.
Its studies are mostly in Heart Failure · Macular Degeneration · Mitochondrial Myopathies · Mitochondrial Diseases · Muscular Diseases, led by Mighty Therapeutics.
Drug pageElamipretide: every studyAll 28 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mighty Therapeutics | 273 open or running | phase 4since Mar 12, 2026 | Apr 30, 2010 | May 2027phase 1 · NCT07927972 |
Also a collaborator on its studies: ICON Clinical Research.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 12 studies since Apr 30, 2010.
- Apr 30, 2015Phase 1 study in Renal InsufficiencyNCT02436447 · 23 enrolled · United States
- Jun 9, 2015Named elamipretideINNProposed as its International Nonproprietary Name in WHO's List 113 · before, MTP-131
- Feb 15, 2016Phase 2 study in Optic Atrophy, Hereditary, LeberNCT02693119 · 12 enrolled · United States
- May 27, 2016Phase 2 study in Heart FailureNCT02788747 · 71 enrolled · Italy, Netherlands, United Kingdom
- Jun 8, 20162 phase 2 studiesNCT02814097, NCT02805790
- Jul 25, 2016Phase 1 study in Macular DegenerationNCT02848313 · 40 enrolled · United States
- Sep 14, 2016Phase 2 study in Heart FailureNCT02914665 · 308 enrolled · Belgium, Bulgaria, France and more
- Nov 18, 2016Phase 2 study in Primary Mitochondrial DiseaseNCT02976038 · 28 enrolled · United States
- Mar 21, 2017Phase 3 study in Barth SyndromeNCT03098797 · 12 enrolled · United States
- Oct 12, 2017Phase 3 study in Muscular DiseasesNCT03323749 · 218 enrolled · United States, Canada, Denmark and more
- Mar 25, 2019Phase 2 study in Macular DegenerationNCT03891875 · 176 enrolled · United States
- Dec 8, 2021Phase 3 study in Mitochondrial MyopathiesNCT05162768 · 102 enrolled · United States, Australia, Germany and more
- Apr 16, 2024Phase 3 study in Macular DegenerationNCT06373731 · 313 enrolled · United States, Czechia, Germany and more
- Mar 12, 2026Phase 4 study in Barth SyndromeNCT07531251 · 48 planned · United States, Australia, Canada and more
- Oct 23, 2026Phase 1 study in Barth SyndromeNCT07927972 · 6 planned
Ahead
- May 2027Primary completion: phase 1 study in Barth SyndromeNCT07927972
- Aug 2027Primary completion: phase 3 study in Macular DegenerationNCT06373731
- Sep 30, 2029Primary completion: phase 4 study in Barth SyndromeNCT07531251
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07927972Barth Syndrome | 1 | Not yet recruiting | May 2027 | 6 |
| NCT07531251Barth Syndrome · United States, Australia, Canada and more | 4 | Recruiting | Sep 30, 2029 | 48 |
| NCT06373731Macular Degeneration · United States, Czechia, Germany and more | 3 | Active, not recruiting | Aug 2027 | 313 |
| NCT05162768Mitochondrial Myopathies · United States, Australia, Germany and more | 3 | Completed | Sep 30, 2024 | 102 |
| NCT03891875Macular Degeneration · United States | 2 | Completed | Feb 22, 2022 | 176 |
| NCT03323749Muscular Diseases · United States, Canada, Denmark and more | 3 | Terminated | Feb 10, 2020 | 218 |
| NCT03098797Barth Syndrome · United States | 3 | Completed | Oct 5, 2018 | 12 |
| NCT02976038Primary Mitochondrial Disease · United States | 2 | Terminated | Mar 9, 2020 | 28 |
| NCT02914665Heart Failure · Belgium, Bulgaria, France and more | 2 | Completed | Nov 27, 2017 | 308 |
| NCT02848313Macular Degeneration · United States | 1 | Completed | Mar 16, 2018 | 40 |
| NCT02805790Mitochondrial Myopathies · United States | 2 | Completed | Mar 10, 2017 | 30 |
| NCT02814097Heart Failure · Germany, Serbia | 2 | Completed | May 4, 2017 | 46 |
| NCT02788747Heart Failure · Italy, Netherlands, United Kingdom | 2 | Completed | Sep 2017 | 71 |
| NCT02693119Optic Atrophy, Hereditary, Leber · United States | 2 | Completed | Sep 2019 | 12 |
| NCT02436447Renal Insufficiency · United States | 1 | Completed | Jul 2015 | 23 |
| NCT02388529Heart Failure · Bulgaria | 1 | Withdrawn | Sep 2015 | 0 |
| NCT02388464Heart Failure · Bulgaria | 1 | Completed | Apr 2015 | 36 |
| NCT02367014Mitochondrial Myopathies · United States | 2 | Completed | Apr 2016 | 36 |
| NCT02314299Macular Degeneration · United States | 2 | Completed | May 2015 | 20 |
| NCT02245620Skeletal Muscle Mitochondrial Dysfunction in the Elderly · United States | 2 | Completed | Jul 6, 2016 | 41 |
| NCT01786915Healthy Volunteers · United States | 1 | Completed | Mar 2013 | 30 |
| NCT01755858Renal Artery Obstruction · United States | 2 | Terminated | Dec 2015 | 16 |
| NCT01754818Healthy · United States | 1 | Completed | Jan 2013 | 30 |
| NCT01572909Reperfusion Injury · United States, Germany, Hungary and more | 2 | Completed | Nov 2014 | 300 |
| NCT01518985Healthy Volunteers · United States | 1 | Completed | Mar 2012 | 6 |
| NCT01513200Healthy Volunteers · United States | 1 | Completed | Feb 2012 | 12 |
| NCT01115920Healthy · United States | 1 | Completed | Sep 2010 | 40 |
How it is read
Names in the registry
- “MTP-131”, 11 entries
- “Elamipretide”, 8 entries
- “elamipretide”, 4 entries
- “Bendavia”, 3 entries
- “Bendavia 10mg”, 2 entries
Conditions, from the studies’ own filings
- Heart Failure, 5 studies
- Macular Degeneration, 3 studies
- Mitochondrial Myopathies, 3 studies
- Mitochondrial Diseases, 2 studies
- Muscular Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.